Michael S. Brown - Jun 14, 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**Michael S. Brown
Stock symbol
REGN
Transactions as of
Jun 14, 2021
Transactions value $
-$261,120
Form type
4
Date filed
6/16/2021, 04:02 PM
Next filing
Jun 28, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $631K +1.7K +190.8% $371.40 2.59K Jun 14, 2021 Direct F1
transaction REGN Common Stock Sale -$893K -1.7K -65.61% $525.00 891 Jun 14, 2021 Direct F1
holding REGN Common Stock 5K Jun 14, 2021 by SLAT F2
holding REGN Common Stock 9.35K Jun 14, 2021 by Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1.7K -44.93% $0.00 2.08K Jun 14, 2021 Common Stock 1.7K $371.40 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.